{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidne7mf4v4raprciq7ux26oj6txhck2qrekwxcfdvpujtiagjtveu",
    "uri": "at://did:plc:p3227y2hdjlcc64d55t4c5y4/app.bsky.feed.post/3mkbxpjac2wu2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiho6u5f3gbwwlw3hkvyds75krjj4f4cj7wydark4mqwkqicwnzlkq"
    },
    "mimeType": "image/jpeg",
    "size": 287014
  },
  "path": "/2026/04/24/the-fda-fast-tracks-its-review-of-psilocybin-and-methylone-2-promising-psychedelics/",
  "publishedAt": "2026-04-24T21:05:58.000Z",
  "site": "https://reason.com",
  "tags": [
    "Addiction",
    "Drug Policy",
    "Medicine",
    "Psychedelics",
    "Department of Health and Human Services",
    "Donald Trump",
    "FDA",
    "Psilocybin",
    "Psychology/Psychiatry",
    "PTSD",
    "Regulation",
    "Trump Administration",
    "Veterans"
  ],
  "textContent": "a psychedelic-colored psilocybing mushroom",
  "title": "The FDA Fast-Tracks Its Review of Psilocybin and Methylone, 2 Promising Psychedelics"
}